title: HLA-DR-negative AML (M1 and M2): FLT3 mutations (ITD and D835) and cell-surface antigen expression.
abstract: FLT3 mutations and cell-surface antigen were investigated in 29 DR-negative (DR(-)) M1/M2 AML samples in comparison with 30 DR-positive (DR(+)) M1/M2 AML samples. FLT3-ITD was detected in 59.3% and D835 was detected in 7.4% of the samples. The incidence of FLT3-ITD was higher in the DR(-) group (59.3%) than in the DR(+) group (17.9%; P=0.002). The DR(-) status was associated with the CD34(-) (82.8%), CD7(-) (92.9%) and CD45RO(+) status (76%). Our results indicated that FLT3 mutation is the most common gene alteration found in the DR(-) M1/M2 AML. These results are important for further characterizing this phenotypic AML entity.
authors.affiliation: International Center for Medical Research and Treatment (ICMRT), Graduate School of Medicine, Kobe University, Chuo-Ku, Kobe 650-0017, Japan.
authors.forename: Meilani
authors.initials: M
authors.lastname: Syampurnawati
authors.forename: Eiji
authors.initials: E
authors.lastname: Tatsumi
authors.forename: Kaho
authors.initials: K
authors.lastname: Furuta
authors.forename: Mariko
authors.initials: M
authors.lastname: Takenokuchi
authors.forename: Yuji
authors.initials: Y
authors.lastname: Nakamachi
authors.forename: Seiji
authors.initials: S
authors.lastname: Kawano
authors.forename: Shunichi
authors.initials: S
authors.lastname: Kumagai
authors.forename: Katsuyasu
authors.initials: K
authors.lastname: Saigo
authors.forename: Toshimitsu
authors.initials: T
authors.lastname: Matsui
authors.forename: Takayuki
authors.initials: T
authors.lastname: Takahashi
authors.forename: Ken-Ichi
authors.initials: K
authors.lastname: Nagai
authors.forename: Hiroki
authors.initials: H
authors.lastname: Yabe
authors.forename: Shinichi
authors.initials: S
authors.lastname: Kondo
authors.forename: Yoshitake
authors.initials: Y
authors.lastname: Hayashi
mesh_terms: D000595:Amino Acid Sequence; D018952:Antigens, CD34 / Q000378:metabolism; D019011:Antigens, CD7 / Q000378:metabolism; D000954:Antigens, Surface / Q000378:metabolism*; D006684:HLA-DR Antigens / Q000378:metabolism*; D006801:Humans; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000378:metabolism; D017493:Leukocyte Common Antigens / Q000378:metabolism; D008969:Molecular Sequence Data; D009154:Mutation / Q000235:genetics*; D015514:Oncogene Proteins, Fusion / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012334:RNA, Neoplasm / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D017386:Sequence Homology, Amino Acid; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics* / Q000378:metabolism
chemical_list: D018952:Antigens, CD34; D019011:Antigens, CD7; D000954:Antigens, Surface; D006684:HLA-DR Antigens; D015514:Oncogene Proteins, Fusion; D012333:RNA, Messenger; D012334:RNA, Neoplasm; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3; D017493:Leukocyte Common Antigens